The in vitro activity of Ro 17-2301 was determined and compared with those of aztreonam, ceftazidime, amikacin, and piperacillin against 141 cefotaxime-resistant gram-negative bacilli. Ro 17-2301 was bactericidal, and its activity against the majority of these oganisms was equal or superior to those of ceftazidime, aztreonam, and piperacillin. An inoculum effect of Ro 17-2301 and aztreonam for many Pseudomonas aeruginosa and Enterobacter spp. isolates was demonstrated.
A number of bacterial species have been found to produce a family of naturally occurring and structurally similar monocyclic beta-lactam compounds (6) . The first of the synthetic monobactams, aztreonam, has been reported to show a high degree of activity against beta-lactamaseproducing aerobic gram-negative bacilli, including Pseudomonas spp., and to be stable to the majority of betalactamases produced by these organisms (4-7). It has little or no activity against gram-positive organisms and anaerobes (4, 6) . Ro 17-2301, a more recently developed monobactam, distinct from aztreonam in the deletion of two methyl groups in the side chain at the C-7 position and the addition of an aminocarboxy group in the side chain at the C-4 position of the monobactam structure, appears to be more active in vitro than aztreonam against the Enterobacteriaceae. In contrast to aztreonam, Ro 17-2301 also demonstrates modest activity against Streptococcus pneumoniae and Bacteroides fragilis (8) . In addition, Ro 17-2301 may possess a greater degree of stability than aztreonam to a wide range of plasmid and chromosomally mediated beta-lactamases (K. Okonogi and M. Kuno, Program Abstr. 23rd Intersci. Conf. Antimicrob. Agents Chemother., abstr. no. 325, 1983) . Potential targets for the monobactams are multiply resistant gramnegative bacteria increasingly associated with nosocomial infections (5) . This report summarizes our investigation of the in vitro activity of Ro 17-2301 compared with those of aztreonam and other similarly targeted antimicrobial agents against cefotaxime-resistant aerobic gram-negative bacilli.
Ro 4 h of incubation at 37°C, turbidity was adjusted to a 0.5 McFarland standard. The standardized suspensions were then diluted 1:10 to achieve a cell density of approximately 107 CFU/ml. A multipoint replicator (Cathra, St. Paul, Minn.), designed to deliver 0.001 ml, was used to inoculate approximately 104 CFU per spot to the surface of the antibiotic-containing agar. Plates were inoculated from the lowest to the highest concentration of antibiotic to avoid carry-over. The MIC, defined as the lowest concentration of antibiotic at which there was no visible growth, was determined after overnight incubation at 37°C. MICs of Ro 17-2301 and aztreonam for 57 Enterobacter spp. and 34 Pseudomonas aeruginosa isolates were also determined by using a microtiter broth dilution technique to determine the inoculum effect. Briefly, bacterial suspensions were obtained as described above and adjusted to contain 108 CFU/ml. Standardized suspensions were then diluted to final concentrations of either 107 or 104 CFU/ml. National Committee for Clinical Laboratory Standards bulk broth dilution schemes were used to prepare the antimicrobial solutions, and 100-pl aliquots were added to each well in 96-well microtiter trays. The wells were then inoculated with 100 [LI of bacterial suspension at a final concentration of either 107 or 104 CFU/ml. The same bacterial inocula were added to media containing 50 p.g of amikacin per ml in Mueller-Hinton broth to allow for the comparison of visual turbidity and bacterial button size in the wells when bacteria did not grow or lyse. The MIC was determined visually after incubation for 24 h at 37°C. The MIC was defined as the lowest concentration of the antibiotic that prevented visible growth in the wells.
The MBCs of Ro 17-2301 and aztreonam for 57 Enterobacter spp. and 34 P. aeruginosa isolates were determined by inoculating Trypticase soy agar plates containing 5% sheep blood with an appropriate subculture volume to assure 
